Skip to main content

Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 24, 2024.

By Dennis Thompson HealthDay Reporter

THURSDAY, Oct. 24, 2024 -- Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says.

People with type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer’s compared to patients taking seven other diabetes drugs, researchers reported Oct. 24 in the journal Alzheimer’s & Dementia.

The results jibe with other studies that have found semaglutide might protect against dementia, said lead researcher Rong Xu, a biomedical informatics professor with Case Western Reserve School of Medicine, in Cleveland.

“This new study provides real-world evidence for its impact on Alzheimer’s disease, even though preclinical research has suggested that semaglutide may protect against neurodegeneration and neuroinflammation,” Xu said in a Case Western news release.

Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy. These medications mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.

For the study, researchers analyzed three years of health records for nearly 1 million U.S. patients with type 2 diabetes.

They found that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s disease, compared to those taking seven other diabetes meds.

However, they warned that more research is needed to confirm this potential benefit.

“Our results indicate that further research into semaglutide’s use will need to be further investigated through randomized clinical trials so alternative drugs can be tested as potential treatment for this debilitating illness,” Xu said.

Sources

  • Case Western Reserve University, news release, Oct. 24, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted October 2024

Read this next

GLP-1 Drugs Appear To Lower Cancer Risk

MONDAY, May 19, 2025 — Cutting-edge GLP-1 weight-loss drugs appear to help lower cancer risk even beyond the benefits from dropping excess pounds, a new study...

Couch Potatoes Have Greater Risk Of Brain Decline, Even If They Exercise

MONDAY, May 19, 2025 — Couch potatoes are more likely to develop Alzheimer’s disease, even if they set aside time to work out each day, a new study says. People who...

FDA Gives Marketing Nod to Blood Test for Diagnosing Alzheimer Disease

FRIDAY, May 16, 2025 -- The first in vitro diagnostic device that uses blood samples to detect Alzheimer disease has been granted marketing clearance by the U.S. Food and Drug...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.